Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-20 pm EDT			5-day change	1st Jan Change
749.41 ^USD	-0.15%		+0.40%	-2.91%

Apr. 15	Sanofi and Regeneron?s Dupixent approval in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	CI
Apr. 15	Sanofi and Regeneron?S Dupixent Approves in the Eu as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI

Transcript : Regeneron Pharmaceuticals, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-04-2026 09

Published on 03/04/2026 at 11:05 am EST - Modified on 04/06/2026 at 03:51 am EDT

S&P Capital IQ

Presenter Speech
Tyler Van Buren (Analysts)

Great. Good morning, everyone. Tyler Van Buren here, senior biotech analyst at TD Cowen. Thank you very much for joining TD Cowen's 46th Annual Healthcare

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Regeneron Pharmaceuticals, Inc.

Apr. 15	Sanofi and Regeneron?s Dupixent approval in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria	CI
Apr. 15	Sanofi and Regeneron?S Dupixent Approves in the Eu as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI
Apr. 13	Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited Announce Strategic Radiopharma Collaboration	CI
Apr. 13	Regeneron, Telix Enter Radiopharma Collaboration; Telix Shares Up Pre-Bell	MT
Apr. 13	Sanofi, Regeneron's Dupixent Becomes First Targeted Treatment for Pediatric Chronic Spontaneous Urticaria in EU	MT
Apr. 13	Regeneron, Sanofi Get Expanded Europe OK for Dupixent in Younger Children With CSU	DJ
Apr. 13	Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI
Apr. 13	Regeneron Pharmaceuticals, Sanofi's Dupixent Recieves EU Approval for Childhood Chronic Hives Treatment	MT
Apr. 13	Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Commission Approval for Dupixent to Treat Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years	CI
Apr. 13	Australian shares slide as US-Iran talks fail, risk appetite sours	RE
Apr. 13	Sanofi, Regeneron Win EU Approval for Chronic Spontaneous Urticaria Treatment in Children	MT
Apr. 12	Telix and Regeneron announce radiopharma collaboration	RE
Apr. 12	Telix Pharmaceuticals, Regeneron Form Radiopharmaceutical Partnership	MT
Apr. 08	Bernstein Adjusts Regeneron Pharmaceuticals Price Target to $921 From $925, Maintains Outperform Rating	MT
Apr. 08	Regeneron Expects $0.81 per Share Net Income Impact From $102 Million R&D Charges for Q1	MT